Abstract
Long-Term Efficacy of Risk-Directed, De-Escalated Post-Operative Adjuvant Therapy for Surgically Resected Locally Advanced, Human Papillomavirus-Positive Oropharynx Squamous-Cell Carcinoma (HPV+ OPSCC): A Non-Randomized, Multi-Arm Phase 2 Trial
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: International Journal of Radiation Oncology, Biology, Physics
Paper Title
Journal
Date